gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PGENHealthcarePharmaceuticals

Precigen, Inc. Common Stock (PGEN)

$5.06−3.71%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$5.05▲ 30.28% in range
Nov 4, 2025Low $3.10 · High $8.56Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Precigen closed at $5.05 on Nov 4, down 3.71%, 40.9% below its 52-week closing high. Volume of 10.5M shares was 1.86× its 20-day average (above normal).

Split-adjusted performance: -33.0% over one month, +14.9% over six months, +21.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $54.98M, up 6322.7% from a year earlier, with a net margin of 36.5%.

Short interest was 46.4M shares at the Oct 15 settlement, down 2.4% from the prior report (26.1% of float, 10.2 days to cover).

Market cap$1.81B358.0M shares
Revenue · quarter$55.0M+6322.7% YoY
Diluted EPS$0.05—
P/E · TTM—P/S 21.1×
Net margin36.5%Gross 94.9%
Dividend yieldNone
52-week range3.10 – 8.56−40.9% from high
Volume10.5M1.86× 20-day avg
Volatility · 60d86.8%Annualised
Short % of float26.1%10.2 days to cover
Net cash-$55.7MCash $38.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.9%1M −33.0%3M −26.8%6M +14.9%YTD +20.9%1Y +21.5%3Y +372.4%5Y +12.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum80
Revenue growth99
Net margin91
Value (low P/E)—
Size79

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short46.4M−2.4% vs prior
Days to cover10.2Settled Oct 15
% of float26.1%
Short vol. 10d55.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PGENPrecigen$5.06−3.71%+14.9%+6322.7%36.5%—$1.81B
BRVEBraveheart Bio$20.11−6.01%————$1.81BCompare
GENBGenerate Biomedicines$14.16+2.24%——−1065.2%—$1.82BCompare
SLSSELLAS Life Sciences Group$9.14+3.04%+77.5%———$1.85BCompare
STOKStoke Therapeutics$27.45+1.70%−17.5%+5.9%−654.3%—$1.77BCompare
ZBIOZenas BioPharma$28.46+0.28%+36.6%—−11145.6%—$1.85BCompare
AGIOAgios Pharmaceuticals$31.38+0.58%+16.3%+259.3%−225.1%—$1.87BCompare
NRIXNurix Therapeutics$15.95−38.23%−5.5%+8426.3%81.7%5.9$1.74BCompare
XERSXeris Biopharma Holdings$10.46+1.06%+64.2%+28.7%−33.8%—$1.91BCompare

News about Precigen

All news →
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss EstimatesZacks Investment Research · 9h agoNeutralPrecigen Gears Up to Report Q3 Earnings: What Can Investors Expect?Zacks Investment Research · 2d ago▼ NegativePrecigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?Zacks Investment Research · Oct 1, 2026▲ PositivePGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research · Sep 30, 2026▲ PositiveWhat Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?The Motley Fool · Jul 15, 2026Neutral

Quick answers

What does Precigen do?
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy.
What is PGEN's market cap?
$1.81B, based on the Nov 4 close of $5.05.
Does Precigen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PGEN is sold short?
46.4M shares, 26.1% of float, as of Oct 15, 2026.
What sector is PGEN in?
Healthcare, in the Pharmaceuticals industry.

About Precigen

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

HQ: Germantown, MD47 employeesListed Aug 8, 2013precigen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology